JP2014513126A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513126A5 JP2014513126A5 JP2014509386A JP2014509386A JP2014513126A5 JP 2014513126 A5 JP2014513126 A5 JP 2014513126A5 JP 2014509386 A JP2014509386 A JP 2014509386A JP 2014509386 A JP2014509386 A JP 2014509386A JP 2014513126 A5 JP2014513126 A5 JP 2014513126A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cell
- composition according
- activated
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 210000000447 Th1 cell Anatomy 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000000961 alloantigen Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 230000000050 nutritive effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482009P | 2011-05-03 | 2011-05-03 | |
| US61/482,009 | 2011-05-03 | ||
| US201161528484P | 2011-08-29 | 2011-08-29 | |
| US61/528,484 | 2011-08-29 | ||
| US201161564551P | 2011-11-29 | 2011-11-29 | |
| US61/564,551 | 2011-11-29 | ||
| US201261582881P | 2012-01-04 | 2012-01-04 | |
| US61/582,881 | 2012-01-04 | ||
| PCT/US2012/036123 WO2012151279A2 (en) | 2011-05-03 | 2012-05-02 | Induction of il-12 using immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079200A Division JP6615148B2 (ja) | 2011-05-03 | 2017-04-12 | 免疫療法を用いたｉｌ−１２の誘導 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513126A JP2014513126A (ja) | 2014-05-29 |
| JP2014513126A5 true JP2014513126A5 (https=) | 2015-06-25 |
| JP6393186B2 JP6393186B2 (ja) | 2018-09-19 |
Family
ID=47108207
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509386A Active JP6393186B2 (ja) | 2011-05-03 | 2012-05-02 | 免疫療法を用いたｉｌ−１２の誘導 |
| JP2017079200A Active JP6615148B2 (ja) | 2011-05-03 | 2017-04-12 | 免疫療法を用いたｉｌ−１２の誘導 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079200A Active JP6615148B2 (ja) | 2011-05-03 | 2017-04-12 | 免疫療法を用いたｉｌ−１２の誘導 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9233156B2 (https=) |
| EP (1) | EP2704732B1 (https=) |
| JP (2) | JP6393186B2 (https=) |
| KR (1) | KR102121492B1 (https=) |
| CN (2) | CN103687602A (https=) |
| AU (3) | AU2012250807A1 (https=) |
| BR (1) | BR112013028285A2 (https=) |
| CA (1) | CA2838046C (https=) |
| IL (1) | IL229177B (https=) |
| PH (1) | PH12013502252B1 (https=) |
| SG (2) | SG194753A1 (https=) |
| WO (1) | WO2012151279A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013028285A2 (pt) | 2011-05-03 | 2017-01-10 | Immunovative Therapies Ltd | indução de il-12 usando imunoterapia |
| WO2015085162A1 (en) | 2013-12-05 | 2015-06-11 | Rfemb Holdings, Llc | Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb) |
| JP6202339B2 (ja) * | 2013-12-19 | 2017-09-27 | 国立研究開発法人国立精神・神経医療研究センター | ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤 |
| US11141216B2 (en) | 2015-01-30 | 2021-10-12 | Immunsys, Inc. | Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue |
| KR20180108655A (ko) | 2016-01-15 | 2018-10-04 | 알에프이엠비 홀딩스, 엘엘씨 | 암의 면역학적 치료 |
| EP3651780A4 (en) * | 2017-07-14 | 2021-04-07 | Minzhen Xu | METHOD FOR INDUCING M1-DOMINATED IMMUNE RESPONSE AND PHARMACEUTICAL COMPOSITIONS |
| US12605349B2 (en) | 2024-09-05 | 2026-04-21 | Orbus Therapeutics, Inc. | Methods of treating grade 3 astrocytoma |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2439003A1 (fr) | 1978-10-20 | 1980-05-16 | Anvar | Nouvelles pieces d'osteosynthese, leur preparation et leur application |
| US5766920A (en) | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
| WO1988000970A2 (en) | 1986-08-08 | 1988-02-11 | Regents Of The University Of Minnesota | Method of culturing leukocytes |
| AU2635088A (en) | 1987-12-04 | 1989-06-08 | Du Pont Merck Pharmaceutical Company, The | Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| JPH0455577A (ja) | 1990-06-22 | 1992-02-24 | Mitsubishi Electric Corp | 構造物の制振装置 |
| WO1994012196A1 (en) | 1992-11-25 | 1994-06-09 | Tanox Biosystems, Inc. | Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules |
| EP0726941B1 (en) | 1993-08-06 | 2002-04-03 | Epimmune Inc. | Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl |
| IL107483A0 (en) | 1993-11-03 | 1994-02-27 | Yeda Res & Dev | Bone marrow transplantation |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| CA2214649C (en) | 1995-03-08 | 2007-06-12 | Zeling Cai | Antigen presenting system and methods for activation of t-cells |
| DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| JPH09255577A (ja) * | 1996-03-27 | 1997-09-30 | Dainippon Ink & Chem Inc | インターリュウキン−１２誘導剤 |
| ES2278390T3 (es) | 1996-05-23 | 2007-08-01 | The Scripps Research Institute | Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+. |
| CA2274004A1 (en) | 1996-12-03 | 1998-06-11 | Osteobiologics, Inc. | Biodegradable polymeric film |
| CA2278847A1 (en) | 1997-01-31 | 1998-08-06 | Hemosol Inc. | Method for the production of selected lymphocytes |
| ATE412383T1 (de) | 1997-05-30 | 2008-11-15 | Osteobiologics Inc | Faserverstärkte,poröse,biologisch abbaubare implantatvorrichtung |
| CA2309206A1 (en) | 1997-11-10 | 1999-05-20 | Arch Development Corporation | Methods for treatment of tumors and tumor cells using ex vivo activated t cells |
| AU4518400A (en) | 1999-07-12 | 2001-01-18 | Isotis B.V. | Sutures |
| US20030119185A1 (en) | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| WO2001062092A1 (en) * | 2000-02-25 | 2001-08-30 | Thomas Jefferson University | Formulations and methods for using the same to elicit an immune response |
| US20020127208A1 (en) | 2000-08-31 | 2002-09-12 | Waller Edmund K. | Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease |
| US6626950B2 (en) | 2001-06-28 | 2003-09-30 | Ethicon, Inc. | Composite scaffold with post anchor for the repair and regeneration of tissue |
| WO2003038062A2 (en) | 2001-10-31 | 2003-05-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Generation of use of tc1 and tc2 cells |
| US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| WO2003053216A2 (en) | 2001-12-06 | 2003-07-03 | University Of Washington | Biodegradable, porous structures useful for growing living tissue, and methods of manufacture |
| US20030175272A1 (en) | 2002-03-07 | 2003-09-18 | Medcell Biologics, Inc. | Re-activated T-cells for adoptive immunotherapy |
| DE10230223A1 (de) | 2002-07-04 | 2004-01-22 | Tegenero Ag | Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern |
| CN1399054A (zh) * | 2002-09-03 | 2003-02-26 | 宋有财 | 旋转式的泊车装置 |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US7371228B2 (en) | 2003-09-19 | 2008-05-13 | Medtronic Vascular, Inc. | Delivery of therapeutics to treat aneurysms |
| US7592431B2 (en) | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
| CA2555714C (en) | 2004-02-26 | 2013-12-03 | Immunovative Therapies, Ltd. | Methods for preparing t-cells for cell therapy |
| US7446099B2 (en) | 2004-02-27 | 2008-11-04 | Nitto Denko Corporation | Compositions and methods for biodegradable polymer-peptide mediated transfection |
| DK1749090T3 (en) | 2004-03-01 | 2017-09-04 | Immunovative Therapies Ltd | CELL THERAPY FORMULATION PROCEDURE AND COMPOSITION |
| US20060036331A1 (en) | 2004-03-05 | 2006-02-16 | Lu Helen H | Polymer-ceramic-hydrogel composite scaffold for osteochondral repair |
| US8865224B2 (en) * | 2004-10-14 | 2014-10-21 | Immunovative Therapies Ltd. | Allogeneic cellular immunotherapy for opportunistic infection |
| WO2007120128A1 (en) | 2006-04-13 | 2007-10-25 | Immunovative Therapies, Ltd. | Allogeneic cell therapy for treatment of opportunistic infection |
| US7972594B2 (en) * | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
| US20080112963A1 (en) | 2006-11-13 | 2008-05-15 | Immunovative Therapies, Ltd. | Ablative immunotherapy |
| EP2025746A1 (en) * | 2007-08-16 | 2009-02-18 | Cell Med Research GMBH | Dendritic cells |
| US20120128656A1 (en) * | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
| BR112013028285A2 (pt) | 2011-05-03 | 2017-01-10 | Immunovative Therapies Ltd | indução de il-12 usando imunoterapia |
-
2012
- 2012-05-02 BR BR112013028285A patent/BR112013028285A2/pt not_active Application Discontinuation
- 2012-05-02 WO PCT/US2012/036123 patent/WO2012151279A2/en not_active Ceased
- 2012-05-02 SG SG2013081302A patent/SG194753A1/en unknown
- 2012-05-02 CN CN201280021818.0A patent/CN103687602A/zh active Pending
- 2012-05-02 CA CA2838046A patent/CA2838046C/en active Active
- 2012-05-02 PH PH1/2013/502252A patent/PH12013502252B1/en unknown
- 2012-05-02 JP JP2014509386A patent/JP6393186B2/ja active Active
- 2012-05-02 KR KR1020137032017A patent/KR102121492B1/ko active Active
- 2012-05-02 AU AU2012250807A patent/AU2012250807A1/en not_active Abandoned
- 2012-05-02 EP EP12779711.6A patent/EP2704732B1/en active Active
- 2012-05-02 US US13/581,745 patent/US9233156B2/en active Active
- 2012-05-02 CN CN201910193492.3A patent/CN109876138A/zh active Pending
- 2012-05-02 SG SG10201901391RA patent/SG10201901391RA/en unknown
-
2013
- 2013-10-31 IL IL229177A patent/IL229177B/en active IP Right Grant
-
2015
- 2015-12-08 US US14/962,728 patent/US11045541B2/en not_active Expired - Fee Related
-
2017
- 2017-04-12 JP JP2017079200A patent/JP6615148B2/ja active Active
- 2017-06-15 AU AU2017204058A patent/AU2017204058A1/en not_active Abandoned
-
2019
- 2019-07-01 AU AU2019204699A patent/AU2019204699A1/en not_active Abandoned
-
2021
- 2021-05-20 US US17/326,009 patent/US11883490B2/en active Active
-
2024
- 2024-01-17 US US18/415,111 patent/US20240148865A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513126A5 (https=) | ||
| Ni et al. | Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors | |
| Sakuishi et al. | TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer | |
| Ye et al. | The significance of tumor necrosis factor receptor type II in CD8+ regulatory T cells and CD8+ effector T cells | |
| Berg et al. | Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells | |
| Uhlin et al. | Adjunct immunotherapies for tuberculosis | |
| Tonn et al. | Treatment of patients with advanced cancer with the natural killer cell line NK-92 | |
| JP2014087372A5 (https=) | ||
| Ben Khelil et al. | Harnessing antitumor CD4+ T cells for cancer immunotherapy | |
| Hailemichael et al. | Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion | |
| MY180750A (en) | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy | |
| Nielsen et al. | Impaired NK cell responses to pertussis and H1N1 influenza vaccine antigens in human cytomegalovirus-infected individuals | |
| JP2018516586A5 (https=) | ||
| JP2017525364A5 (https=) | ||
| CA2642532A1 (en) | Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject | |
| JP2011006491A5 (https=) | ||
| JP2016539929A5 (https=) | ||
| JP2018527932A5 (https=) | ||
| JP5118624B2 (ja) | 新規なヒトｔ細胞集団 | |
| JP6525946B2 (ja) | Ｔｈ１特性と細胞溶解性を発現する細胞 | |
| Roberts et al. | TNF blockade maintains an IL-10+ phenotype in human effector CD4+ and CD8+ T cells | |
| Luo et al. | New insights into the stemness of adoptively transferred T cells by γc family cytokines | |
| Du et al. | Regulatory T cells: concept, classification, phenotype, and biological characteristics | |
| Baumann et al. | Memory CD8+ T cell protection from viral reinfection depends on interleukin-33 alarmin signals | |
| Suck et al. | Emerging natural killer cell immunotherapies: large-scale ex vivo production of highly potent anticancer effectors |